The Evaluation of Efficacy and Safety of Stylage® XL Lidocaïne for the Restoration and/or Augmentation of Facial Volume

Inclusion Criteria: * Healthy Subject; * Sex: male or female; * Age: between 30 and 65 years; * Subject having given freely and expressly his informed consent; * Subject requiring injection on the cheekbones (upper part of the cheek); * Subject with grade from 3 to 5 on the Facial Volume Loss Scale (FVLS); * Subject, psychologically able to understand the study related information and to give a written informed consent; * Subject affiliated to a health social security system; * Female of childbearing potential should use a medically accepted contraceptive regimen since at least 12 weeks before the beginning of the study and during all the study; * Subject agreeing to keep their usual cleansing / care products during the whole study period; * Subject agreeing to apply a Sun Protection Factor (SPF) 50 cream during non-intensive exposure to sunlight. Exclusion Criteria: In terms of population * Pregnant or nursing woman or planning a pregnancy during the study; * Subject with a scar, moles or anything on the face which might interfere with the evaluation; * Subject who had been deprived of their freedom by administrative or legal decision or who is under guardianship; * Subject in a social or sanitary establishment; * Subject participating to another research on human beings or who is in an exclusion period of one; * Subject having received 4500 euros indemnities for participation in researches involving human beings in the 12 previous months, including participation in the present study. * Intensive exposure to sunlight or Ultraviolet-rays (UV-rays) within the month before each visit; In terms of associated pathology * Subject suffering from a severe or progressive disease or any other pathology that may interfere with the evaluation of the study results; * Subject with known history of or suffering from autoimmune disease and/or immune deficiency; * Subject suffering from inflammatory and/or infectious cutaneous disorders in or near the studied zones (herpes, acne, mycosis, papilloma…). Subject with recurrent herpes is not eligible even if asymptomatic at time of inclusion; * Subject prone to develop inflammatory skin conditions or having tendency to bleeding disorders * Subject having history of allergy or anaphylactic shock including hypersensitivity to hyaluronic acid or to one of the components of the tested device; * Subject having history of allergy or anaphylactic shock including hypersensitivity to amide-type local anaesthetics or antiseptic solution; * Subject with a past history of streptococcal disease, such as acute rheumatic fever or recurrent sore throats; * Subject with a tendency to develop keloids or hypertrophic scars; * Subject with haemostatic disorder; * Subject with porphyria; Relating to previous or ongoing treatment * Subject having received treatment with a laser, a dermabrasion, a surgery, a deep chemical peeling or other ablative procedure on the face within the past 12 months prior to inclusion; * Subject having received injection with a resorbable filling product in the face area within the past 18 months prior to inclusion; * Subject having received at any time injection with a slowly resorbable filling product (polylactic acid, calcium hydroxyapatite, combinations of hyaluronic acid (HA) and hypromellose, HA and dextran microbeads or HA and TriCalcium Phosphate (TCP), …) or with a non-resorbable filling product (polyacrylamide, silicone, combination of methacrylic polymers and collagen, polymer particles, …); * Subject having received at any time a treatment with tensor threads on the face; * Subject having started or changed her oral contraceptive or any other hormonal treatment during 12 weeks prior to inclusion; * Subject under medications that reduce or inhibit hepatic metabolism; * Subject under medications which may cause lipo-atrophy; * Subject using medication such as aspirin, NSAIDs (ibuprofen, naproxen, …), antiplatelet agents, anticoagulants, vitamin C within one week prior to inclusion and agreeing not to take such treatments within 1 week prior to visit 2 (M1) or being a chronic user; * Subject undergoing a topical treatment on the test area or a systemic treatment; * anti-histamines during the 2 weeks prior to study start; * immunosuppressors and/or corticoids during the 4 weeks prior to study start; * retinoids during the 6 months prior to study start.